Unless there are upgrades, phase 3 is announced, institutional investors come in - the stock will not go anywhere. It seems with this stock all 3 need to happen, and even one has not happened. They can produce all the great results they want but without advancing the drug to the next step, it is not going to generate any enthusiasm.
I just don't know what will make this stock move forward. AML data has been holding, there is now unexpectedly good MDS data which came out 3 months ago but the stock continues to wallow other than pump and dumps above $2 I am not sure if Dr. Gold announces that pracinostat cures cancer that the stock will move. Very disappointing to say the least
You will see
I will second that, looks hopeless now unfortunately. I held the shares for a long time but sold my position.
From Street Insider:
MannKind's (NASDAQ: MNKD) TASE financing formally canceled, according to market reports.
UPDATE - According to Israel's Calcalist, regulators in Israel are cancelling MannKind's ability to raise money on the TASE. ETFs were supposed to inject MannKind with 400 million amid its entry into the TA-100 and TA-75
The situation is a barrier between the SEC and MannKind which can prevent the company from raising funds in the manner it intended to, according to Calcalist.
The publication noted that "the Israel Securities Authority is investigating the matter but, at the moment there is no decision on the issue."
The ISA is opposing Mutual Fund managers from raising funds for two primary reasons: the current security level and liquidity concerns with another offering without the issue being satisfactorily resolved.
The data looks good so far, it is till Aug 4, the rest of the data to be presented from that date onwards at ASH is of the greatest importance. Sell of at the news going on a lot with biotechs
ASH Abstract Data till Aug 4 showing beneficial effect in AML patients. Also in MDS patients who did not drip out showing significant benefit. Remaining most crucial data from Aug 4 onwards will be presented at ASH. So far so good. Abstract was entirely in line with expectations and what was discussed in monthly conferences. Hold on to your shares, the manipulated sell off will not last long, ASH is the biggest catalyst ever for this stock and should be expected to run up with just a month remeaining,
Jump is after SA article today, will have to see if it can break and hold above $2. Abstracts will be published tomorrow. Unless it can clear the lower $2's and stay above it, it will be just same pump and dump
meip can move quick, it moved up $3 before March intern data release in less than a month. So a lot cound happen in the next 5 weeks
Median survival on AML patients has not yet been reached yet, this is good news. That means that more than 50% of patients on the drug are still alive, the drug in on track to generate good data. We will have full data at ASH, but if this update is accurate, it it on track to robust data indeed.
Doubt it. If the conference next week is good, it should keep moving up considering ASH is not too far off.
It needs to break and hold above low $2's, then that would peak buyers interest..Still has a way to go, too many fake runs